Other Mutations: DNA damage repair mutations

NCT05417594: Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

NCT05417594
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations: BRCA+, DNA damage repair mutations,
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 1|Phase 2
Drug Category: Misc Inhibitor, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 130 Years (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: 
Exclusions: Breast cancer patients are only eligible for Module 1 Parts A & B
https://ClinicalTrials.gov/show/NCT05417594

NCT05128825: A Study of ZN-c3 in Subjects With Malignant Tumors

NCT05128825
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: BRCA+, DNA damage repair mutations, ATM, ATR
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with prior therapy of ZN-c3 or any other WEE1 inhibitor
https://ClinicalTrials.gov/show/NCT05128825

Up ↑